Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds bacterium or component thereof or substance produced...
Reexamination Certificate
2005-11-29
2005-11-29
Smith, Lynette R.F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds bacterium or component thereof or substance produced...
C424S184100
Reexamination Certificate
active
06969520
ABSTRACT:
The invention provides active and passive immunization methods for preventing and treatingClostridium difficileinfection, which involve percutaneous administration ofC. difficiletoxin-neutralizing polyclonal immune globulin,C. difficiletoxoids, or combinations thereof. Also provided by the invention areC. difficiletoxoids,C. difficiletoxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produceC. difficiletoxin-neutralizing polyclonal immune globulin.
REFERENCES:
patent: 5412077 (1995-05-01), Siber et al.
patent: 5530102 (1996-06-01), Gristina et al.
patent: 5582827 (1996-12-01), Siber et al.
patent: 5599539 (1997-02-01), Carroll et al.
patent: 5601823 (1997-02-01), Williams et al.
patent: 5762934 (1998-06-01), Williams et al.
patent: 5773000 (1998-06-01), Bostwick et al.
patent: 5919665 (1999-07-01), Williams
patent: WO 94/13264 (1994-06-01), None
patent: WO 96/07430 (1996-03-01), None
patent: WO 96/12802 (1996-05-01), None
patent: WO 97/02836 (1997-01-01), None
patent: WO97/09886 (1997-03-01), None
patent: WO 97/09886 (1997-03-01), None
Kotloff et al., (“Safety and Immunogenicity of Increasing Doses of a Clostridium difficile Toxoid Vaccine Administered to Healthy Adults”, Infection and Immunity, (Feb. 2001) 69(2) 988-9.
Torres et al., (Evaluation of Formalin-Inactivated Clostridium difficile Vaccines Administered by Parenteral and Mucosal Routes of Immunization in Hamsters, Infection and Immunity, Dec. 1995, p 4619-4627).
Allo et al., “Prevention of Clindamycin-Induced Colitis in Hamsters byClostridium sordelliAntitoxin,”Gastroenterology76:351-355 (1979).
Corthler et al., “Protection against Experimental Pseudomembranous Colitis in Gnotobiotic Mice by Use of Monoclonal Antibodies AgainstClostridium difficileToxin A,”Infection and Immunity59:1192-1195 (1991).
Fekety et al., “Diagnosis and Treatment ofClostridium difficileColitis,”Journal of the American Medical Association269:71-75 (1993).
Fernie et al., “Active and Passive Immunization to Protect Against Antibiotic Associated Caecitis in Hamsters,”Dev. Biol. Stand. 53:325-332 (1983).
Johnston, “Antibody Responses to Clostridial Infection in Humans,”Clinical Infectious Diseases25:2 S173-177 (1997).
Johnson et al., “Systemic and Mucosal Antibody Reponses to Toxin A in Patients Infected with Clostridium Difficile,”Journal of Infectious Diseases166:1287-1294 (1992).
Kelly et al., “Anti-Clostridium difficileBovine Immunoglobulin Concentrate Inhibits Cytotoxicity and Enterotoxicity of C.difficileToxins,”AntiMicrobial Agents and Chemotherapy40:373-379 (1996).
Kim et al., “Immunization of Adult Hamsters againstClostridium difficile-Associated Ileocecitis and Transfer of Protection to Infant Hamsters,”Infection and Immunity55:2984-2992 (1987).
Kyne et al., “Prospects for a vaccine forClostridium difficile,” BioDrugs10:173-181 (1998).
Leung et al., “Treatment with Intravenously Administered Gamma Globulin of Chronic Relapsing Colitis Induced byClostridium difficileToxin,”The Journal of Pediatrics118:633-637 (1991).
Libby et al., “Effects of the Two Toxins ofClostridium difficileand Immunological Comparison of the Toxins by Cross-Neutralization Studies,”Infection and Immunity36:822-829 (1982).
Libby et al., “Production of Antitoxins of Two Toxins ofClostridium difficileand immunological Comparison of the Toxins by Cross-Neutralization Studies,”Infection and Immunity35:374-376 (1982).
Lyerly et al., “Passive Immunization of Hamsters Against Disease Caused byClostridium Difficileby use of Bovine Immunoglobulin G Concentrate,”Infection and Immunity59:2215-2218 (1991).
Lyerly et al., “Vaccination Against LethalClostridium DifficileEnterocolitis with a Nontoxic Recombinant Peptide of Toxin A,”Current Microbiology21:29-32 (1990).
Mitty et al., “Clostridium difficileDiarrhea: Pathogenesis, Epidemiology, and Treatment,”The Gastroenterologist2:61-69 (1994).
Mulligan et al., “Elevated Levels of Serum Immunoglobulins in Asymptomatic Carriers of Clostridium Difficile,”Clinic of Infectious DiseasesSuppl 4:S239-244 (1993).
Salcedo et al., “Intravenous Immunoglobulin Therapy for SevereClostridium difficileColitis,”Gut41:366-370 (1997).
Torres et al., “Clostridium difficileVaccine: Influence of Different Adjuvants and Routes of Immunization on Protective Immunity in Hamsters,”Vaccine Research 5:149-162 (1996).
Torres et al., “Evaluation of Formalin-InactivatedClostridium difficileVaccines Administered by Parenteral and Mucosal Routes of Immunization in Hamsters,”Infection and Immunity63:4619-4627 (1995).
Wamy et al., “Gamma Globulin Administration In RelapsingClostridium difficile-Induced Pseudomembranous Colitis with Defective Antibody Response to Toxin A,”Acta Clinica Belgica50:36-39 (1995).
Giannasca Paul J.
Lei Wende
Monath Thomas P.
Thomas, Jr. William D.
Zhang Zhenxi
Acambis Inc.
Clark & Elbing LLP
Smith Lynette R.F.
Tongue Lakia
LandOfFree
Active immunization against clostridium difficile disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Active immunization against clostridium difficile disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Active immunization against clostridium difficile disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3497969